The stereospecific compounds may be a novel technique for the treatment of non-small cell lung cancer (NSCLC).

Zhao Y, Turlington M, LaPar DJ, Jones DR, Harris DA, Kron IL, Pu L, Lau CL. "Ann Thorac Surg. 2011 Sep"

BACKGROUND,

With the exception of surgical treatment, the normal platinum-based chemotherapeutic agents are the favored remedy for non-small cell lung cancer (NSCLC), nevertheless little improvement (5-year survival) continues to be produced. Therefore it really is highly fascinating to create revolutionary therapeutic agents for NSCLC remedy.

METHODS,

Highly enantioselective artificial techniques had been developed as well as a broad Screening Library was proven. Cell toxicity, cell sensitivity, cell proliferation, cell invasion, and three-dimensional colony formation assays were utilized to evaluate the anticancer potential of these compounds in non-small-cell lung cancer (NSCLC) cell lines.

RESULTS,

We identified thepowerful anticancer exercise in 5 tested NSCLC cell lines. We additional synthesized a very pure R-form enantiomer of PL54 (PL54R) and its racemate (PL54Rac) and characterised their anticancer actions.

The results showed that PL54S is far more powerful than PL54R and PL54Rac towards the tested cell lines. Furthermore, much less mobile toxicity was observed in the regular human lung fibroblasts.

Similarly, PL54S shown greater anti-colony formation action in comparison with PL54R and PL54Rac. The mobile sensitivity assay exposed that PL54S and PL54Rac drastically suppressed cologenic formation comparedmight prove to become a novel method for your therapy of non-small-cell lung cancer (NSCLC).